UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 26 von 12143
Datensatz exportieren als...
BibTeX
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Cancer, 2016-02, Vol.122 (3), p.367-377
Harding, James J.
Dika, Imane
Abou‐Alfa, Ghassan K.
2016
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Harding, James J.
Dika, Imane
Abou‐Alfa, Ghassan K.
Titel
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Ist Teil von
Cancer, 2016-02, Vol.122 (3), p.367-377
Ort / Verlag
United States
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared toward manipulating the immune response to HCC have suggested a therapeutic benefit in early‐stage clinical trials, indicating a real potential to augment tumor‐specific immunity and improve outcomes in patients with this disease. In the current study, the authors reviewed the barriers to an effective immune response against HCC and contemporary clinical investigations that may be “primed” to alter the natural history of HCC. Cancer 2016;122:367–377. © 2015 American Cancer Society. Hepatocellular carcinoma evades the immune response via several mechanisms. This review focuses on the immunobiology of hepatocellular carcinoma and novel methods to develop effective immunotherapies for this deadly disease.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.29769
Titel-ID: cdi_proquest_miscellaneous_1785232684
Format
–
Schlagworte
Antibodies, Monoclonal - therapeutic use
,
Antineoplastic Agents - immunology
,
Antineoplastic Agents - therapeutic use
,
B7-H1 Antigen - antagonists & inhibitors
,
Cancer Vaccines - therapeutic use
,
Carcinoma, Hepatocellular - immunology
,
Carcinoma, Hepatocellular - therapy
,
checkpoint inhibitors
,
Clinical Trials as Topic
,
CTLA-4 Antigen - antagonists & inhibitors
,
Cytokines - therapeutic use
,
Hepatitis, Chronic - immunology
,
hepatocellular carcinoma
,
Humans
,
immune evasion
,
immunotherapy
,
Immunotherapy - methods
,
Interferons - therapeutic use
,
Liver Neoplasms - immunology
,
Liver Neoplasms - therapy
,
Oncolytic Virotherapy - methods
,
Programmed Cell Death 1 Receptor - antagonists & inhibitors
,
Pyrazoles - therapeutic use
,
Quinolines - therapeutic use
,
T-Lymphocytes - immunology
,
Tumor Escape
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX